Fisher & Paykel Healthcare Corporation Limited (FPH)

 NULL
   
  • 52 Week High: NULL
  • 52 Week Low: $19.73
  • Currency: Australian Dollars
  • Shares Issued: 573.76m
Select chart: 1 week | 1 month | 3 month | 6 month | 1 year
 

Current

1 week

Forecasts

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-25 1,996.22 487.57 n/a n/a n/a -100% n/a 0.0%
31-Mar-26 2,242.59 588.24 n/a n/a n/a n/a n/a 0.0%
31-Mar-27 2,515.06 705.20 n/a n/a n/a n/a n/a 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

Forecast Ratios

Year Ending Revenue/Share Price/Revenue per Share
31-Mar-25 $3.48 9.43
31-Mar-26 $3.91 8.39
31-Mar-27 $4.38 7.48

Trends & Recommendations

  Current 1 week ago 1 month ago 3 months ago 6 months ago 1 year ago
Revenue ($m)
31-Mar-2025 1,996 1,996 1,997 1,962 1,958 1,913
31-Mar-2026 2,243 2,243 2,244 2,188 2,188 2,123
31-Mar-2027 2,515 2,515 2,518 2,436 n/a n/a
 
Earnings
31-Mar-2025 n/a n/a n/a n/a n/a n/a
31-Mar-2026 n/a n/a n/a n/a n/a n/a
31-Mar-2027 n/a n/a n/a n/a n/a n/a
 
Dividend
31-Mar-2025 n/a n/a n/a n/a n/a n/a
31-Mar-2026 n/a n/a n/a n/a n/a n/a
31-Mar-2027 n/a n/a n/a n/a n/a n/a
 
Recommendations
Strong Buy 1 1 1 1 2 1
Buy 0 0 0 0 0 0
Neutral 7 7 7 7 6 6
Sell 4 4 4 4 3 3
Strong Sell 0 0 0 0 0 1
No. of Brokers 12 12 12 12 11 11
 
Average Rec 4.58 4.58 4.58 4.58 5.23 4.32

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are end of day values only.

Note 2: Broker estimates sourced from FactSet Estimates +44 (0) 20 3009 7000. FactSet Estimates calculate consensus using only those estimates changed or actively validated within the last 75 days.

Note 3: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 4: Forecast figures based on normalised accounts.

 

FPH Market Data

Currency Australian Dollars
% Change 0.00 %
52 Week High NULL
52 Week Low $19.73
Shares Issued 573.76m

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 7
Sell 4
Strong Sell 0
Total 12
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Top of Page